TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 5, 2007, Pages 487-491

  Zhang, Hong ^a   Wang, Yue Shu ^b   Han, Gang ^a   Shi, Ying ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Hepatocarcinoma; Metalloproteinases; Neoplasm invasion

Indexed keywords

COMPLEMENTARY DNA; LIPOFECTAMINE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; EXPRESSION VECTOR; EXTRACELLULAR MATRIX; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTASIS; METASTASIS POTENTIAL; MICROVASCULATURE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA, NEOPLASM; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFECTION;

EID: 34948831072     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 2001;195:135-137.
2. Ulrich D, Lichtenegger F, Eblenkamp M, Repper D, Pallua N. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants. Hast Reconstr Surg 2004;114:229-236.
3. Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005;11:3046-3050.
4. Jung K, Meisser A, Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005;116:1000-1001; author reply 1002-1003.
5. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 2006;6:19.
6. Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655-666.
7. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-1152.
8. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998;153:1895-1902.
9. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999;79:1347-1355.
10. Xiao M, Zhou NX, Huang ZQ, Lu YL, Chen LH, Wang DJ, et al. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004;3:599-602.
11. Jiang Y, Wang M, Celiker MY, Liu YE, Sang QX, Goldberg ID, et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001;61:2365-2370.
12. Noel A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-273.
13. Noel A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM, et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000;19:1605-1612.
14. Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev 2000;10:120-127.
15. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997;272:31730-31737.
16. Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004;11:928-933.
17. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9:1441-1447.
18. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004;10:634-640.
19. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006;233:98-107.
20. Ozen O, Krebs B, Hemmerlein B, Pekrun A, Kretzschmar H, Herms J. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. Clin Cancer Res 2004;10:4746-4753.